{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:21:14Z","timestamp":1785943274147,"version":"3.56.0"},"reference-count":285,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Ovarian cancer is the deadliest gynecologic cancer in individuals assigned female at birth. Patients diagnosed with ovarian cancer experience poor survival rates due to frequent late-stage diagnosis and aggressive metastases. Ovarian cancer is often diagnosed at stages III or IV, where survival rates decline substantially. Ovarian cancer comprises several subtypes, each with distinct biological characteristics, clinical behaviors, and treatment responses, thereby complicating the identification of effective therapeutic targets. This review focuses primarily on the most prevalent subtype, high-grade serous carcinoma (HGSC) while also considering less common subtypes such as low-grade serous carcinoma, endometrioid carcinoma, clear cell and mucinous carcinomas. The tumor microenvironment (TME) plays a central role in tumor progression, metastasis, and immune evasion, thereby influencing therapeutic response and patient outcomes. Therefore, understanding the interactions between cancer cells and their microenvironment is essential for developing innovative therapeutic strategies. By identifying subtype-specific biomarkers and disease mechanisms, we can enhance diagnostic accuracy and develop tailored treatment approaches. A deeper understanding of ovarian cancer subtypes and their unique characteristics is vital for advancing patient care, driving innovations in early detection, and ultimately improving survival rates in this complex disease. This review emphasizes the potential for identifying novel biomarkers within the TME, which could facilitate earlier diagnosis and the development of targeted treatments for specific ovarian cancer subtypes, ultimately reducing mortality rates in this challenging cancer landscape.<\/jats:p>","DOI":"10.3389\/fonc.2026.1876327","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:30:14Z","timestamp":1785414614000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diversity within ovarian cancer subtypes and their tumor microenvironment"],"prefix":"10.3389","volume":"16","author":[{"given":"Lacey","family":"Winstone","sequence":"first","affiliation":[{"name":"Cancer Research Group, College of Medicine, University of Saskatchewan","place":["Saskatoon, SK, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanne","family":"Bevelander","sequence":"additional","affiliation":[{"name":"Cancer Research Group, College of Medicine, University of Saskatchewan","place":["Saskatoon, SK, Canada"]},{"name":"Department of Biochemistry, Microbiology & Immunology, College of Medicine, University of Saskatchewan","place":["Saskatoon, SK, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Dean","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Cancer Research Group, College of Medicine, University of Saskatchewan","place":["Saskatoon, SK, Canada"]},{"name":"Department of Biochemistry, Microbiology & Immunology, College of Medicine, University of Saskatchewan","place":["Saskatoon, SK, Canada"]},{"name":"Department of Oncology, College of Medicine, College of Medicine, University of Saskatchewan","place":["Saskatoon, SK, Canada"]},{"name":"Department of Discovery and Translational Research, Saskatchewan Cancer Agency","place":["Saskatoon, SK, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","unstructured":"Cancer Statistics at a Glance\n          \n          \n          \n          2024"},{"key":"B2","unstructured":"Ovarian Cancer Statistics & Survival Rates"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"B4","unstructured":"How is Ovarian Cancer Diagnosed\n          \n          \n            \n              DeMarco\n              C\n            \n          \n          \n          2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signaling"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2011.09.001","article-title":"The tumor microenvironment","volume":"21","author":"Weber","year":"2012","journal-title":"Surg Oncol"},{"key":"B8","first-page":"1","article-title":"MicroRNAs: The master regulators of the breast cancer tumor microenvironment","volume-title":"Handbook of Oxidative Stress in Cancer: Therapeutic Aspects","author":"Feser","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092053","article-title":"The role of tumor microenvironment in cancer metastasis: Molecular mechanisms and therapeutic opportunities","volume":"13","author":"Neophytou","year":"2021","journal-title":"Cancers"},{"key":"B14","unstructured":"What Causes Hereditary Breast and Ovarian Cancers\n          \n          \n          \n          2024"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.bjc.6600008","article-title":"A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes","volume":"86","author":"Antoniou","year":"2002","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer","volume":"3","author":"Ramus","year":"2009","journal-title":"Mol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.05.007","article-title":"PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations","volume":"103","author":"Kolasa","year":"2006","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1999.tb00793.x","article-title":"Mutational analysis of STK11 h gene in ovarian carcinomas","volume":"90","author":"Nishioka","year":"1999","journal-title":"Jpn J Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","article-title":"Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: A rereview of cases lacking tp53 mutations in the cancer genome atlas ovarian study","volume":"35","author":"Vang","year":"2016","journal-title":"Int J Gynecological Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2478\/v10042-009-0039-6","article-title":"Mutations in the KRAS gene in ovarian tumors","volume":"47","author":"Dobrzycka","year":"2009","journal-title":"Folia Histochem Cytobiol"},{"key":"B23","unstructured":"Long term health consequences of polycystic ovarian syndrome: a review analysis\n          \n          \n            \n              Daniilidis\n              A\n            \n            \n              Dinas\n              K\n            \n          \n          Hippokratia\n          \n          2009"},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ygyno.2015.01.537","article-title":"Hereditary predisposition to ovarian cancer, looking beyond BRCA1\/BRCA2","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9210","article-title":"Endometriosis typology and ovarian cancer risk","volume":"332","author":"Barnard","year":"2024","journal-title":"JAMA"},{"key":"B26","unstructured":"Ovarian Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"B28","unstructured":"Ovarian Cancer - Symptoms and Causes\n          \n          \n          2025"},{"key":"B29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajog.2020.06.049","article-title":"Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer","volume":"223","author":"Frey","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-018-0384-1","article-title":"The molecular mechanism of ovarian granulosa cell tumors","volume":"11","author":"Li","year":"2018","journal-title":"J Ovarian Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/reprodmed3020011","article-title":"Ovarian cancer: Treatment and resistance to pharmacotherapy","volume":"3","author":"Lukanovi\u0107","year":"2022","journal-title":"Reprod Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/S11523-023-00970-W","article-title":"PARP inhibitors in ovarian cancer: A review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/S13048-024-01362-Y","article-title":"PARP inhibitor era in ovarian cancer treatment: A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Barad\u00e1cs","year":"2024","journal-title":"J Ovarian Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4132\/KoreanJPathol.2014.48.4.327","article-title":"Dedifferentiated endometrioid adenocarcinoma of the uterus: Highly aggressive and poor prognostic tumor","volume":"48","author":"Park","year":"2014","journal-title":"J Pathol Transl Med"},{"key":"B40","unstructured":"High Grade Serous Carcinoma\n          \n          \n            \n              Forg\u00f3\n              E\n            \n            \n              Longacre\n              TA\n            \n          \n          \n          2020"},{"key":"B41","unstructured":"Low Grade Serous Carcinoma\n          \n          \n            \n              Forg\u00f3\n              E\n            \n            \n              Longacre\n              TA\n            \n          \n          \n          2020"},{"key":"B42","unstructured":"Endometrioid Carcinoma\n          \n          \n            \n              Saglam\n              O\n            \n          \n          \n          2021"},{"key":"B43","unstructured":"Clear Cell Carcinoma\n          \n          \n            \n              Turashvili\n              G\n            \n          \n          \n          2021"},{"key":"B44","unstructured":"Mucinous Carcinoma\n          \n          \n            \n              Zanfagnin\n              V\n            \n            \n              Devins\n              K\n            \n          \n          \n          2025"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10797","article-title":"Ovarian low and high grade serous carcinomas: Hidden divergent features in the tumor microenvironment","volume":"7","author":"Ciucci","year":"2016","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.72705","article-title":"Ovarian cancer genetics: Subtypes and risk factors","volume-title":"Ovarian Cancer - From Pathogenesis to Treatment","author":"Hirst","year":"2018"},{"key":"B47","unstructured":"Mucinous Tumours: Mucinous Borderline Tumor\n          \n          \n            \n              Nilforoushan\n              N\n            \n            \n              Vang\n              R\n            \n          \n          \n          2021"},{"key":"B48","unstructured":"Undifferentiated \/ Dedifferentiated Carcinoma (Endometrium \/ Ovary)\n          \n          \n            \n              Tessier-Cloutier\n              B\n            \n          \n          \n          2022"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2767-9764.CRC-22-0410","article-title":"Trends of ovarian cancer incidence by histotype and race\/ethnicity in the United States 1992\u20132019","volume":"3","author":"Phung","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B52","unstructured":"2024"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11345","article-title":"Pathology and classification of ovarian tumors","volume":"97","author":"Chen","year":"2003","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/159799","article-title":"Molecular features as promising biomarkers in ovarian cancer","volume":"32","author":"Buk\u0142aho","year":"2023","journal-title":"Adv Clin Exp Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0147-0272(92)90047-r","article-title":"Ovarian cancer, part I: Biology","volume":"16","author":"Hamilton","year":"1992","journal-title":"Curr Probl Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5275","article-title":"The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes","volume":"72","author":"Dubeau","year":"1999","journal-title":"Gynecol Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0090-8258(03)00365-2","article-title":"BRCA1\/2-related ovarian cancers are of tubal origin: a hypothesis","volume":"90","author":"Piek","year":"2003","journal-title":"Gynecol Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin Med Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Levanon","year":"2008","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/S13244-021-01004-7","article-title":"Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists","volume":"12","author":"Amante","year":"2021","journal-title":"Insights Imaging"},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: A review and proposal","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecological Pathol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PAP.0B013E3181B4FFFA","article-title":"Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1674-8301(10)60036-X","article-title":"Morphological and molecular basis of ovarian serous carcinoma","volume":"24","author":"Rosen","year":"2010","journal-title":"J BioMed Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020458","article-title":"Low-grade serous carcinoma of the ovary: The current status","volume":"12","author":"Babaier","year":"2022","journal-title":"Diagnostics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"23742895211032340","DOI":"10.1177\/23742895211032339","article-title":"Educational case: High-grade serous carcinoma of the ovary","volume":"8","author":"Bunde","year":"2021","journal-title":"Acad Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.03.010","article-title":"Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","volume":"141","author":"Dao","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143465","article-title":"Mutated p53 in HGSC\u2014From a common mutation to a target for therapy","volume":"13","author":"Saleh","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102666","article-title":"Spatial tumor evolution panorama of ovarian cancer","volume":"7","author":"Feng","year":"2026","journal-title":"Cell Rep Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142269","article-title":"Association of tumor-infiltrating lymphocytes and inflammation status with survival outcome in patients with high-grade serous ovarian carcinoma","volume":"17","author":"Miceska","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B70","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/S13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases","volume":"13","author":"Suszynska","year":"2020","journal-title":"J Ovarian Res 2020 13:1"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1449543","article-title":"The role of STK11\/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression","volume":"12","author":"Kang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2009.50.2.266","article-title":"Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women","volume":"50","author":"Cho","year":"2009","journal-title":"Yonsei Med J"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1292","article-title":"Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver","volume":"20","author":"Emmanuel","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/PATH.6338","article-title":"Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma","volume":"264","author":"Vallejos","year":"2024","journal-title":"J Pathol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100629","article-title":"Epithelial ovarian cancer","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13679","article-title":"Endometrioid ovarian carcinoma landscape: Pathological and molecular characterization","volume":"18","author":"de Nonneville","year":"2024","journal-title":"Mol Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPZ5T2POOFMQVN","article-title":"Distinct \u03b2-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas","volume":"144","author":"Matsumoto","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/MODPATHOL.2013.107","article-title":"Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles","volume":"27","author":"McConechy","year":"2014","journal-title":"Mod Pathol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-7-19","article-title":"A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients","volume":"7","author":"Zhang","year":"2014","journal-title":"J Ovarian Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.02.010","article-title":"Clinicopathological characteristics of mucinous adenocarcinoma of the ovary","volume":"113","author":"Shimada","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2014.04.008","article-title":"Mucins and tumor resistance to chemotherapeutic drugs","volume":"1846","author":"Jonckheere","year":"2014","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/S12885-015-1421-8","article-title":"Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms","volume":"15","author":"Mackenzie","year":"2015","journal-title":"BMC Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003704","article-title":"New therapies for clear cell ovarian carcinoma","volume":"33","author":"Stewart","year":"2023","journal-title":"Int J Gynecological Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.07.005","article-title":"ARID1A mutation\/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer","volume":"162","author":"Kuroda","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am J Pathol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2017.12.005","article-title":"Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing","volume":"148","author":"Kim","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.41","article-title":"Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms","volume":"23","author":"Tafe","year":"2010","journal-title":"Mod Pathol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.188","article-title":"SWI\/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma","volume":"7","author":"Tessier-Cloutier","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/MODPATHOL.2016.156","article-title":"Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas","volume":"29","author":"Coatham","year":"2016","journal-title":"Mod Pathol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S67812","article-title":"A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology","volume":"7","author":"Chen","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx446","article-title":"Acquired chemotherapy resistance in ovarian cancer","volume":"28","author":"Christie","year":"2017","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstetrics Gynecology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e31827630eb","article-title":"Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: A clinicopathologic study of 32 patients from a population-based tumor registry","volume":"32","author":"Ali","year":"2013","journal-title":"Int J Gynecological Pathol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduction Targeted Ther 2023 8:1"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group Metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2020.01.021","article-title":"Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes","volume":"157","author":"Scott","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B100","unstructured":"Pathology Outlines - Endometrioid Carcinoma"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000550","article-title":"Morphological and immunohistochemical re-evaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors","volume":"40","author":"Lim","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1186\/s12885-023-11048-1","article-title":"An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer 2023 23:1"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061676","article-title":"Endometriosis-associated ovarian cancer: The origin and targeted therapy","volume":"12","author":"Murakami","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2022.902371","article-title":"Endometriosis is undervalued: A call to action","volume":"3","author":"Ellis","year":"2022","journal-title":"Front Glob Womens Health"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084306","article-title":"Endometriosis-associated ovarian cancer: From molecular pathologies to clinical relevance","volume":"25","author":"Steinbuch","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B107","unstructured":"Ovarian Cancer: Symptoms, Diagnosis & Treatment"},{"key":"B108","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jogc.2016.10.006","article-title":"Endometrioid carcinoma of the ovary: Outcomes compared to serous carcinoma after 10 years of follow-up","volume":"39","author":"Bouchard-Fortier","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2014.25.2.118","article-title":"Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: Analysis in Japanese women","volume":"25","author":"Yoshikawa","year":"2014","journal-title":"J Gynecol Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10552-013-0174-4","article-title":"Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case\u2013control studies","volume":"24","author":"Faber","year":"2013","journal-title":"Cancer Causes Control"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19221","article-title":"Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10010052","article-title":"Mucinous cancer of the ovary: Overview and current status","volume":"10","author":"Babaier","year":"2020","journal-title":"Diagnostics"},{"key":"B113","unstructured":"Pathology Outlines - Mucinous Carcinoma"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000473","article-title":"Survival of patients with mucinous ovarian carcinoma and ovarian metastases: A population-based cancer registry study","volume":"25","author":"Simons","year":"2015","journal-title":"Int J Gynecological Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13863","article-title":"Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010","volume":"45","author":"Nagase","year":"2019","journal-title":"J Obstetrics Gynaecology Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040869","article-title":"Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma","volume":"12","author":"Khan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B117","unstructured":"Pathology Outlines - Clear Cell Carcinoma"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.7150\/jca.61107","article-title":"Endometriosis-associated ovarian clear cell carcinoma: a special entity","volume":"12","author":"Sun","year":"2021","journal-title":"J Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"18797","DOI":"10.1038\/s41598-024-69796-4","article-title":"Integrated genomic\/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin","volume":"14","author":"Nishijima","year":"2024","journal-title":"Sci Rep"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2024.5705","article-title":"Beyond tumor-associated macrophages involved in spheroid formation and dissemination: novel insights for ovarian cancer therapy (review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int J Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ijc.1215","article-title":"Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)","volume":"92","author":"Borgfeldt","year":"2001","journal-title":"Int J Cancer"},{"key":"B122","unstructured":"Pathology Outlines - Undifferentiated \/ Dedifferentiated Carcinoma (Endometrium \/ Ovary)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100374","article-title":"Dedifferentiated and undifferentiated ovarian carcinoma: an aggressive and molecularly distinct ovarian tumor characterized by frequent SWI\/SNF complex inactivation","volume":"37","author":"Tessier-Cloutier","year":"2024","journal-title":"Mod Pathol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9350","article-title":"Unclassified mixed germ cell-sex cord-stromal tumor of the ovary: an unusual case report","volume":"12","author":"Saenz","year":"2020","journal-title":"Cureus"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.02.007","article-title":"Ovarian cancer incidence in the United States, 1992-1999","volume":"97","author":"Quirk","year":"2005","journal-title":"Gynecol Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092050","article-title":"Ovarian germ cell tumors: pictorial essay","volume":"12","author":"Gic\u0103","year":"2022","journal-title":"Diagnostics"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2003.50103","article-title":"Epithelial ovarian tumors in children: a retrospective analysis","volume":"38","author":"Morowitz","year":"2003","journal-title":"J Pediatr Surg"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.016261","article-title":"Ovarian sex cord-stromal tumors","volume":"12","author":"Schultz","year":"2016","journal-title":"J Oncol Pract"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.038","article-title":"Ovarian sex cord\u2013stromal tumors in children and adolescents","volume":"21","author":"Schneider","year":"2003","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100866","article-title":"Mimicking and analyzing the tumor microenvironment","volume":"4","author":"Crouigneau","year":"2024","journal-title":"Cell Rep Methods"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1042\/BST20231427","article-title":"Mechanoimmunology in the solid tumor microenvironment","volume":"52","author":"Golo","year":"2024","journal-title":"Biochem Soc Trans"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.03.027","article-title":"Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","volume":"86","author":"Schoutrop","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09935-1","article-title":"The role of caspase-8 in the tumor microenvironment of ovarian vancer","volume":"40","author":"Kostova","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0383","article-title":"TGF\u03b2 signaling regulates epithelial\u2013mesenchymal plasticity in ovarian cancer ascites-derived spheroids","volume":"23","author":"Rafehi","year":"2016"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am J Pathol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2014.18.263.4903","article-title":"Primary fallopian tube carcinoma: a case report","volume":"18","author":"Boufettal","year":"2014","journal-title":"Pan Afr Med J"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091270","article-title":"Fallopian tube basal stem cells reproducing the epithelial sheets in vitro\u2014stem cell of fallopian epithelium","volume":"10","author":"Zhu","year":"2020","journal-title":"Biomolecules"},{"key":"B140","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s42003-024-05826-1","article-title":"Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer","volume":"7","author":"Chai","year":"2024","journal-title":"Commun Biol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0296","article-title":"Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41388-021-02139-z","article-title":"Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence","volume":"41","author":"Kan","year":"2022","journal-title":"Oncogene"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm1831","article-title":"Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer","volume":"8","author":"Zhang","year":"2022","journal-title":"Sci Adv"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1001789","article-title":"Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis","volume":"12","author":"Schwarz","year":"2015","journal-title":"PloS Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J Clin Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006412","article-title":"Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors","volume":"4","author":"Milne","year":"2009","journal-title":"PloS One"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225488","article-title":"Regulatory T cells in ovarian carcinogenesis and future therapeutic opportunities","volume":"14","author":"Cassar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070894","article-title":"B cells as an immune-regulatory signature in ovarian cancer","volume":"11","author":"Gupta","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061899","article-title":"Cancer-associated fibroblasts: Master tumor microenvironment modifiers","volume":"15","author":"Wright","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B151","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbadis.2016.11.006","article-title":"The role of \u03b1-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling","volume":"1863","author":"Shinde","year":"2017","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0002","article-title":"The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance","volume":"2","author":"Fearon","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B154","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191094","article-title":"Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21","volume":"217","author":"Hussain","year":"2020","journal-title":"J Exp Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851705000232","article-title":"The role of pericytes in blood-vessel formation and maintenance","volume":"7","author":"Bergers","year":"2005","journal-title":"Neuro Oncol"},{"key":"B157","article-title":"Blood vessels and endothelial cells","volume-title":"Molecular Biology of the Cell. 4th Edition","author":"Alberts","year":"2002"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1530\/VB-19-0032","article-title":"Tumour vessel remodelling: new opportunities in cancer treatment","volume":"2","author":"Ganss","year":"2020"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8805","article-title":"Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma","volume":"10","author":"Xu","year":"2024","journal-title":"Sci Adv"},{"key":"B160","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.GOX.0001015704.18680.41","article-title":"SP35. Characterizing cancer associated fibroblasts across millions of tumor cells","volume":"12","author":"Korah","year":"2024","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14112637","article-title":"The role of cancer-associated fibroblasts in ovarian cancer","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119801","article-title":"Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype","volume":"1871","author":"Axemaker","year":"2024"},{"key":"B163","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41419-022-05129-5","article-title":"ARTICLE CRMP2 derived from cancer associated fibroblasts facilitates progression of ovarian cancer via HIF-1\u03b1-glycolysis signaling pathway","volume":"13","author":"Jin","year":""},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1010428317712592","article-title":"Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1\/FGFR4 signaling","volume":"39","author":"Sun","year":"2017","journal-title":"Tumor Biol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10587","article-title":"Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer","volume":"18","author":"Sun","year":"2019","journal-title":"Oncol Lett"},{"key":"B166","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/egjp.egjp_12_19","article-title":"Cancer-associated fibroblasts in epithelial ovarian carcinoma: Relation to clinicopathologic characteristics and microvessel density","volume":"39","author":"Abdel Kerim","year":"2019","journal-title":"Egyptian J Pathol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41590-025-02248-x","article-title":"Targeting CAFs","volume":"26","author":"Bernard","year":"2025","journal-title":"Nat Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1504762","article-title":"Cancer-associated fibroblasts in ovarian cancer: Research progress","volume":"15","author":"Xu","year":"2025","journal-title":"Front Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":""},{"key":"B170","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41467-018-03348-z","article-title":"miR200-regulated CXCL12\u03b2 promotes fibroblast heterogeneity and immunosuppression in ovarian cancers","volume":"9","author":"Givel","year":"2018","journal-title":"Nat Commun"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133136","article-title":"The effects of chemotherapeutics on the ovarian cancer microenvironment","volume":"13","author":"Eckert","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1126\/SCIADV.ABB0737","article-title":"Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs","volume":"7","author":"Yang","year":"2021","journal-title":"Sci Adv"},{"key":"B173","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41467-025-67557-z","article-title":"Ovarian cancer metastasis to the human omentum disrupts organ homeostasis and induces fundamental tissue reprogramming","volume":"17","author":"Lischetti","year":"2025","journal-title":"Nat Commun 2025 17:1"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310859","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38014","article-title":"Exploring tumor microenvironment in molecular subtyping and prognostic signatures in ovarian cancer and identification of SH2D1A as a key regulator of ovarian cancer carcinogenesis","volume":"10","author":"Guo","year":"2024","journal-title":"Heliyon"},{"key":"B176","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12885-022-10404-x","article-title":"PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers","volume":"23","author":"Alwosaibai","year":"2023","journal-title":"BMC Cancer"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1661048","article-title":"The immunotherapy era in ovarian clear cell carcinoma: Current evidence and future perspective","volume":"16","author":"Passarelli","year":"2025","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/J.YGYNO.2026.05.017","article-title":"Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival","volume":"210","author":"Smick","year":"2026","journal-title":"Gynecol Oncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: From mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13048-024-01359-7","article-title":"From clinical management to personalized medicine: Novel therapeutic approaches for ovarian clear cell cancer","volume":"17","author":"Liu","year":"2024","journal-title":"J Ovarian Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.03.002","article-title":"Immunological functions of the omentum","volume":"38","author":"Meza-Perez","year":"2017","journal-title":"Trends Immunol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100366","article-title":"Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy","volume":"10","author":"Gupta","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.04.023","article-title":"Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models","volume":"183","author":"Clark","year":"2013","journal-title":"Am J Pathol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4375","article-title":"Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice","volume":"67","author":"Robinson-Smith","year":"2007","journal-title":"Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0300","article-title":"Humanized patient-derived xenograft models of disseminated ovarian cancer recapitulate key aspects of the tumor immune environment within the peritoneal cavity","volume":"3","author":"Steinkamp","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2537710","article-title":"Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response","volume":"14","author":"Nikeghbal","year":"2025"},{"key":"B188","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","article-title":"Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells","volume":"40","author":"Anadon","year":"2022","journal-title":"Cancer Cell"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003329","article-title":"CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer","volume":"9","author":"Muthuswamy","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi112","article-title":"Tumour-infiltrating gamma\/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma","volume":"16","author":"Raspollini","year":"2005","journal-title":"Ann Oncol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejcsup.2019.12.002","article-title":"Inflammation and immunity in ovarian cancer","volume":"15","author":"Salas-Benito","year":"2020","journal-title":"EJC Suppl"},{"key":"B193","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-16555-9","volume-title":"The Extracellular Matrix: An Overview","author":"Mecham","year":"2011"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15776","article-title":"A guide to the composition and functions of the extracellular matrix","volume":"288","author":"Karamanos","year":"2021","journal-title":"FEBS J"},{"key":"B195","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","article-title":"Extracellular matrix structure","volume":"97","author":"Theocharis","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010238","article-title":"The functional role of extracellular matrix proteins in cancer","volume":"14","author":"Popova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00245","article-title":"The extracellular matrix in epithelial ovarian cancer \u2013 a piece of a puzzle","volume":"5","author":"Cho","year":"2015","journal-title":"Front Oncol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jbio.201200108","article-title":"Second harmonic generation microscopy as a powerful diagnostic imaging modality for human ovarian cancer","volume":"7","author":"Adur","year":"2014","journal-title":"J Biophotonics"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74778","article-title":"Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion","volume":"124","author":"Kenny","year":"2014","journal-title":"J Clin Invest"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.02.017","article-title":"Tenascin-C induced signaling in cancer","volume":"244","author":"Orend","year":"2006","journal-title":"Cancer Lett"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/208017","article-title":"Secretome identifies tenascin-X as a potent marker of ovarian cancer","volume":"2015","author":"Kramer","year":"2015","journal-title":"BioMed Res Int"},{"key":"B202","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-95730-4.00012-3","article-title":"Recent developments in 3D bioprinting for neural tissue engineering","volume-title":"Handbook of Neural Engineering","author":"Sharma","year":"2025"},{"key":"B203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-811385-1.00004-2","article-title":"Design considerations when engineering neural tissue from stem cells","volume-title":"Engineering Neural Tissue From Stem Cells","author":"Willerth","year":"2017"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2018.19.9.2493","article-title":"Fibronectin regulates the dynamic formation of ovarian cancer multicellular aggregates and the expression of integrin receptors","volume":"19","author":"Gong","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"B205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2024.04.002","article-title":"Tenascin-C targeting strategies in cancer","volume":"130","author":"Dhaouadi","year":"2024","journal-title":"Matrix Biol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009743","article-title":"IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors","volume":"12","author":"Wickman","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2020.100021","article-title":"Loss of tenascin-X expression during tumor progression: a new pan-cancer marker","author":"Liot","year":"2020","journal-title":"Matrix Biol Plus"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1107787","article-title":"Tenascin-X as a causal gene for classical-like Ehlers-Danlos syndrome","volume":"14","author":"Okuda-Ashitaka","year":"2023","journal-title":"Front Genet"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2013.06.005","article-title":"Tenascin-X, collagen, and Ehlers-Danlos syndrome: Tenascin-X gene defects can protect against adverse cardiovascular events","volume":"81","author":"Petersen","year":"2013","journal-title":"Med Hypotheses"},{"key":"B210","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13048-025-01752-w","article-title":"Functional study of laminin subunit \u03b15 in high-grade serous ovarian cancer","volume":"18","author":"Tianli","year":"2025","journal-title":"J Ovarian Res"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300306R","article-title":"LAMA5 promotes cell proliferation and migration in ovarian cancer by activating Notch signaling pathway","volume":"37","author":"Diao","year":"2023","journal-title":"FASEB J"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/J.ISCI.2022.103923","article-title":"Spatially resolved transcriptomics of high-grade serous ovarian carcinoma","volume":"25","author":"Stur","year":"2022","journal-title":"iScience"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.777018","article-title":"Chronic stress: impacts on tumor microenvironment and implications for anti-cancer treatments","volume":"9","author":"Tian","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100558","article-title":"Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer","volume":"26","author":"Aquino-Acevedo","year":"2022","journal-title":"Brain Behav Immun Health"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41350","article-title":"The ovary: basic biology and clinical implications","volume":"120","author":"Richards","year":"2010","journal-title":"J Clin Invest"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.827032","article-title":"Estrogen biosynthesis and signal transduction in ovarian disease","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B217","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.psyneuen.2004.06.003","article-title":"Diurnal cortisol rhythm and fatigue in breast cancer survivors","volume":"30","author":"Bower","year":"2005","journal-title":"Psychoneuroendocrinology"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1177\/1534735410370036","article-title":"Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer","volume":"9","author":"Jehn","year":"2010","journal-title":"Integr Cancer Ther"},{"key":"B219","article-title":"Physiology, stress reaction","volume-title":"Statpearls","author":"Chu","year":"2025"},{"key":"B220","article-title":"What are ovaries","volume-title":"Cleveland Clinic","year":"2025"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-1-73","article-title":"Estrogen, progesterone and epithelial ovarian cancer","volume":"1","author":"Ho","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00192","article-title":"Estrogen biosynthesis and action in ovarian cancer","volume":"5","author":"Mungenast","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2023.e00500","article-title":"Ovarian high-grade serous carcinoma with estrogenic manifestations in a postmenopausal woman: a case report","volume":"37","author":"Takeda","year":"2023","journal-title":"Case Rep Womens Health"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.04.324","article-title":"Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma","volume":"130","author":"Matsuo","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s12672-024-01675-w","article-title":"Sex hormones and immune regulation in ovarian cancer","volume":"15","author":"Zhao","year":"2024","journal-title":"Discover Oncol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2004.03.026","article-title":"Estrogens and epithelial ovarian cancer","volume":"94","author":"Cunat","year":"2004","journal-title":"Gynecol Oncol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040909","article-title":"The impact of estrogens and their receptors on immunity and inflammation during infection","volume":"14","author":"Harding","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2022.01.003","article-title":"Testosterone-secreting endometrioid ovarian carcinoma presenting with hyperandrogenism","volume":"8","author":"Rajamani","year":"2022","journal-title":"AACE Clin Case Rep"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:29:2:271","article-title":"Progesterone-induced neuroprotection","volume":"29","author":"Singh","year":"2006","journal-title":"Endocrine"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi064","article-title":"Genetic variation in the progesterone receptor gene and ovarian cancer risk","volume":"161","author":"Terry","year":"2005","journal-title":"Am J Epidemiol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Llaurado Fernandez","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B232","article-title":"Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.018","article-title":"Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNF\u03b1 in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy","volume":"108","author":"Bamias","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1042\/CS20240346","article-title":"The endothelin-1-driven tumor-stroma feed-forward loops in high-grade serous ovarian cancer","volume":"138","author":"Tocci","year":"2024","journal-title":"Clin Sci"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.09.059","article-title":"TGF\u03b2 and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells","volume":"401","author":"Xu","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.1998.00757.x","article-title":"Cytokines: principles and prospects","volume":"76","author":"Kelso","year":"1998","journal-title":"Immunol Cell Biol"},{"key":"B237","article-title":"Cytokines, chemokines and their receptors","volume-title":"Madame Curie Bioscience Database","author":"Cameron","year":"2013"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12445","article-title":"Co\u2010operative roles of IL\u20104R\u03b1 and IL\u201013R\u03b11 in the progression of ovarian carcinomas and the survival of ovarian carcinoma patients","volume":"43","author":"Choi","year":"2023","journal-title":"Cancer Commun"},{"key":"B239","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"key":"B240","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.22666","article-title":"Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer","volume":"121","author":"Szlosarek","year":"2007","journal-title":"Int J Cancer"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.2741\/3066","article-title":"TNF: a master switch for inflammation to cancer","volume":"13","author":"Sethi","year":"2008","journal-title":"Front Biosci"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.2478\/v10042-008-0117-1","article-title":"Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer","volume":"47","author":"Dobrzycka","year":"2010","journal-title":"Folia Histochem Cytobiol"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2941","article-title":"The inflammatory cytokine tumor necrosis factor-\u03b1 generates an autocrine tumor-promoting network in epithelial ovarian cancer cells","volume":"67","author":"Kulbe","year":"2007","journal-title":"Cancer Res"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9282","article-title":"p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11121335","article-title":"Elevated interleukin-6 levels in the circulation and peritoneal fluid of patients with ovarian cancer as a potential diagnostic biomarker: a systematic review and meta-analysis","volume":"11","author":"Amer","year":"2021","journal-title":"J Pers Med"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0623","article-title":"Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine","volume":"65","author":"Nilsson","year":"2005","journal-title":"Cancer Res"},{"key":"B247","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J Exp Med"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1002\/art.11143","article-title":"Anti\u2013interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2017.1360342","article-title":"Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer","volume":"46","author":"Sanguinete","year":"2017","journal-title":"Immunol Invest"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1126\/science.2161559","article-title":"Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI","volume":"248","author":"Moore","year":"1990","journal-title":"Sci (1979)"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2010.0188","article-title":"Expression of IL-10 in human normal and cancerous ovarian tissues and cells","volume":"21","author":"Rabinovich","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/1043-4666(92)90082-3","article-title":"Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers","volume":"4","author":"Gotlieb","year":"1992","journal-title":"Cytokine"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-018-0215-3","article-title":"Ascites IL-10 promotes ovarian cancer cell migration","volume":"11","author":"Lane","year":"2018","journal-title":"Cancer Microenviron"},{"key":"B257","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21037\/cco-23-135","article-title":"Interleukine-10 in ovarian cancer","volume":"13","author":"Levin","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"B258","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1006\/gyno.1995.1103","article-title":"Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system","volume":"57","author":"DeCesare","year":"1995","journal-title":"Gynecol Oncol"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.05.024","article-title":"High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer","volume":"118","author":"Wolf","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0317115","article-title":"Deciphering ovarian cancer heterogeneity through spatial transcriptomics, single-cell profiling, and copy number variations","volume":"20","author":"Li","year":"2025","journal-title":"PloS One"},{"key":"B262","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1038\/s41467-024-47271-y","article-title":"Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones","volume":"15","author":"Denisenko","year":"2024","journal-title":"Nat Commun 2024 15:1"},{"key":"B263","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/J.HUMPATH.2020.01.002","article-title":"High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy","volume":"98","author":"Wiedemeyer","year":"2020","journal-title":"Hum Pathol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1309\/49LA9XCBGWJ8F2KM","article-title":"Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer","volume":"129","author":"P\u00e9rigny","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9366-x","article-title":"Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer","volume":"27","author":"Zohny","year":"2010","journal-title":"Med Oncol"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.796588","article-title":"Expression of TIMPs and MMPs in ovarian tumors, ascites, ascites-derived cells, and cancer cell lines: characteristic modulatory response before and after chemotherapy treatment","volume":"11","author":"Escalona","year":"2022","journal-title":"Front Oncol"},{"key":"B267","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/sjmms.sjmms_581_21","article-title":"NGAL\/MMP-9 as a biomarker for epithelial ovarian cancer: a case-control diagnostic accuracy study","volume":"10","author":"Gupta","year":"2022","journal-title":"Saudi J Med Med Sci"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15121521","article-title":"Matrix metalloproteinases 1 and 3 in ovarian cancer: diagnostic and prognostic potential of genetic variants and expression profiling","volume":"15","author":"Mackawy","year":"2025","journal-title":"Diagnostics"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2017.08.004","article-title":"Overview of transcriptomic analysis of all human proteases, non-proteolytic homologs and inhibitors: organ, tissue and ovarian cancer cell line expression profiling of the human protease degradome by the CLIP-CHIPTM DNA microarray","volume":"1864","author":"Kappelhoff","year":"2017","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.32.4.757","article-title":"Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis","volume":"32","author":"Pulukuri","year":"2008","journal-title":"Int J Oncol"},{"key":"B271","doi-asserted-by":"publisher","first-page":"18785","DOI":"10.1038\/s41598-019-55266-9","article-title":"Structural studies of the MMP-3 interaction with triple-helical collagen introduce new roles for the enzyme in tissue remodelling","volume":"9","author":"Manka","year":"2019","journal-title":"Sci Rep"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2010.0188","article-title":"Parallel overexpression of seven kallikrein genes in ovarian cancer1,2","volume":"63","author":"Yousef","year":"2003","journal-title":"Cancer Res"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/946572","article-title":"Involvement of kallikrein-related peptidases in normal and pathologic processes","volume":"2015","author":"Stefanini","year":"2015","journal-title":"Dis Markers"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1111\/febs.70080","article-title":"The protease ADAMTS5 controls ovarian cancer cell invasion, downstream of Rab25","volume":"292","author":"Yuan","year":"2025","journal-title":"FEBS J"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1432","article-title":"Association of somatic mutations of ADAMTS genes with chemotherapy sensitivity and survival in high-grade serous ovarian carcinoma","volume":"1","author":"Liu","year":"2015","journal-title":"JAMA Oncol"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1332043","article-title":"Specific changes in amino acid profiles in monocytes of patients with breast, lung, colorectal and ovarian cancers","volume":"14","author":"Chagovets","year":"2023","journal-title":"Front Immunol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1172\/JCI196348","article-title":"Citrullination in tumor immunity and therapy","volume":"135","author":"Pitter","year":"2025","journal-title":"J Clin Invest"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb06554.x","article-title":"Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses","volume":"905","author":"Xiao","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10070227","article-title":"Lysophospholipid signaling in the epithelial ovarian cancer tumor microenvironment","volume":"10","author":"Xu","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat Med"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092267","article-title":"Regulatory role of the adipose microenvironment on ovarian cancer progression","volume":"14","author":"Chehade","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.14.6379","article-title":"Fatty acid synthesis: a potential selective target for antineoplastic therapy","volume":"91","author":"Kuhajda","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.05.085","article-title":"Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells","volume":"385","author":"Grunt","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.07.027","article-title":"Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells","volume":"353","author":"Yellen","year":"2014","journal-title":"Cancer Lett"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0093-z","article-title":"Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis","volume":"37","author":"Ladanyi","year":"2018","journal-title":"Oncogene"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:42:50Z","timestamp":1785940970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":285,"alternative-id":["10.3389\/fonc.2026.1876327"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1876327","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1876327"}}